In its biggest deal since its $46.8 billion takeover of Genentech in 2009, Swiss drug giant Roche has turned to Davis Polk & Wardwell for counsel on its $8.3 billion buy of suburban San Francisco-based lung disease drug developer InterMune, which is being advised by Cravath, Swaine & Moore and a Chicago IP boutique.
August 25, 2014 at 06:12 PM
1 minute read
Roche Holding announced Monday its $8.3 billion acquisition of InterMune, a suburban San Francisco-based company lung disease drug developer, marking the latest in a series of deals by the Swiss drug giant.
The proposed purchase of InterMune is Roche’s largest deal since its $46.8 billion takeover of Genentech in 2009, and second major deal this summer following Roche’s $1.7 billion buy of San Diego-based Seragon Pharmaceuticals in July.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
Duane Morris LLP seeks a highly motivated junior associate to join its dynamic and growing Labor and Employment Class Action group in Chicag...
Duane Morris LLP seeks a full-time staff litigation attorney who has practiced between 3-5 years. Experience will include drafting motions, ...
Duane Morris LLP has an immediate opening for a senior level, highly motivated litigation associate to join its dynamic and growing Employme...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
The American Lawyer provides the most informed and trusted source of news, data, analysis and forecasting on the global business of law.
